Tubigon, Jesse .

HRN: 25-94-93  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/27/2024
CEFTRIAXONE 1G (VIAL)
09/27/2024
10/04/2024
IV
2gm
OD
CELLULITIS
Waiting Final Action 
09/27/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
09/27/2024
10/04/2024
IV
600MG
Q6
CELLULITIS
Waiting Final Action 
10/02/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/02/2024
10/08/2024
IV
4.5 G LOADING DOSE THEN 2.25 G
Q8
CELLLULITIS, LEFT L EG
Waiting Final Action 
10/02/2024
CLINDAMYCIN 300MG (CAP)
10/02/2024
10/08/2024
ORAL
300 MG
Q6
INFECTED WOUND, LOWER LIP
Waiting Final Action 
10/05/2024
MUPIROCIN 2%, 15G (TUBE)
10/05/2024
10/11/2024
TOPICAL
2%
BID
Infected Wound Left Foot
Waiting Final Action 
10/09/2024
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
10/09/2024
10/15/2024
IVTT
500 Mg
OD
Cellulitis, Sepsis
Waiting Final Action 
10/09/2024
LEVOFLOXACIN 500MG (TAB)
10/09/2024
10/15/2024
PO
500 Mg/tab, 1 Tab
OD
Cellulitis, Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: